We spend a lot of waking hours attending to our gastrointestinal system, that is, the gastrointestinal tract (GIT).

Datapharm has conducted several GIT studies from phases II to IV. Starting at the top end we’ve looked at oral mucositis in lymphoma patients undergoing chemotherapy and stem cell transplantation. This was a phase II study of a product designed to help patients through what can be an extremely painful and debilitating side effect of necessary treatment.

We’ve investigated treatments for vomiting or emesis, and studies on gastric reflux and gastrooesophageal reflux disease have featured prominently among our phase III and IV studies. Datapharm also has experience in non-ulcer dyspepsia to determine effectiveness of a treatment for helicobacter pylori. Datapharm has also been involved in a number of studies for non-alcoholic fatty liver/nonalcoholic steatohepatitis (NASH).

Recently Datapharm has been involved in a post marketing study for Crohn’s disease covering Australia and New Zealand. Our team and gastroenterology clinical trials network is also currently involved in a constipation predominant Irritable Bowel Syndrome (IBS-C) clinical trial.

To find out more about clinical trial capabilities in Australia and New Zealand for the gastroenterology area get in touch!

To find out more about this capability contact us today.